Juniper Pharma (JNP) Tops Q3 EPS by 17c; Enters Agreement to Monetize Crinone Royalty Payments

November 15, 2016 8:29 AM EST
Get Alerts JNP Hot Sheet
Trade JNP Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Juniper Pharma (NASDAQ: JNP) reported Q3 EPS of $0.02, $0.17 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $11.6 million versus the consensus estimate of $10.35 million.

Juniper also announced it has entered into an agreement with its partner, Allergan, Inc. (NYSE: AGN) to monetize future royalty payments due to Juniper for U.S. sales of Crinone (progesterone gel). Under the agreement, Juniper will receive a one-time payment of $11 million from Allergan.

"The monetization of our U.S. Crinone royalty stream significantly strengthens our balance sheet and provides non-dilutive cash to support our near-term strategic and operational goals," said Alicia Secor, Juniper's President and Chief Executive Officer.

The Company sold U.S. Crinone® rights to Allergan in July 2010; since then, Juniper has received from Allergan a 10% royalty on its U.S. Crinone® sales.

Juniper will continue as the exclusive supplier of Crinone® for all markets outside the U.S. and receive revenue from sales to Merck KGaA, Darmstadt, Germany ("Merck KGaA"). Merck KGaA holds the marketing authorization for Crinone® in over 90 countries.

Approved in the U.S. in 1997, Crinone® is indicated for supplementation or replacement as part of an Assisted Reproductive Technology (ART) treatment for infertile women with progesterone deficiency.

For earnings history and earnings-related data on Juniper Pharma (JNP) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Earnings, Management Comments

Related Entities


Add Your Comment